{"id":"W4387868674","doi":"10.1016/s0140-6736(23)01962-1","title":"IMbrave050: the first step towards adjuvant therapy in hepatocellular carcinoma","year":2023,"lang":"en","type":"letter","venue":"The Lancet","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Medicine; Sorafenib; Hepatocellular carcinoma; Internal medicine; Bevacizumab; Atezolizumab; Oncology; Adjuvant therapy; Regorafenib; Adjuvant; Cancer; Gastroenterology; Nivolumab; Colorectal cancer; Chemotherapy; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002459232,0.0006968467,0.001691107,0.0006140548,0.001399113,0.002909993,0.001092329,0.03123287,0.006741687],"category_scores_gemma":[0.01190715,0.0004942135,0.001256553,0.0005689787,0.001795524,0.002737606,0.001090706,0.02615618,0.008340916],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003171778,"about_ca_system_score_gemma":0.0024731,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002599228,"about_ca_topic_score_gemma":0.005647869,"domain_scores_codex":[0.9983771,0.0005899196,0.0001962116,0.0001182078,0.0004773476,0.0002411739],"domain_scores_gemma":[0.9962336,0.001998533,0.0002980024,0.0001232742,0.0004470955,0.0008994843],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004670596,0.00009015859,0.0007795034,0.0001714555,0.00003981709,0.001556328,0.00005374992,0.000189587,0.0006155791,0.004051957,0.9478477,0.04413698],"study_design_scores_gemma":[0.001004379,0.000463545,0.002622561,0.0009002012,0.00009715481,0.002378867,0.0001780262,0.001096405,0.0006548435,0.02170655,0.9688004,0.00009721579],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"editorial","genre_scores_codex":[0.0006574261,0.009188554,0.0001740004,0.9586883,0.02497256,0.00001777033,0.0001119806,0.00004138935,0.006148092],"genre_scores_gemma":[0.01056548,0.007962053,0.0004523719,0.8483815,0.1215635,0.00006268841,0.0001249827,0.00004891528,0.01083838],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.03123287,"threshold_uncertainty_score":0.02301294,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1133943063750961,"score_gpt":0.2707579540425069,"score_spread":0.1573636476674108,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}